Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow INMB by emailGet an email when INMB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about INMB, unsubscribe in one click. Privacy
📣 What INMB Says Is Next
in 2026 · “We have taken on board their advice regarding data analyses for the phase III trial required for substantive approval, which is expected to open in 2026.”
Company press release, Jun 23, 2026 · SEC filing
this year · “With our planned BLA submission targeted for later this year, we are well-positioned to potentially benefit from this important incentive as we work to bring CORDStrom™ to RDEB patients who urgently need new options.” CORDStrom is potentially the first systemic treatment designed to address the severe unmet symptoms of RDEB patients.”
Company press release, Feb 13, 2026 · SEC filing
the end of 2026 · “Following the planned MAA submission to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), we anticipate submitting a Biologics License Application (BLA) to the U.S. FDA toward the end of 2026.”
Company press release, Jan 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full INMB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for INMB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.